Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Date:7/28/2011

THE WOODLANDS, Texas, July 28, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 clinical trial of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).  Lexicon plans to move LX1033 forward into a Phase 2 study in patients with IBS-d.

Top-line results demonstrated that LX1033 was well tolerated at all doses and produced a statistically significant reduction in serotonin synthesis compared to placebo, as measured by both plasma (p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin synthesis. Importantly, a greater reduction in serotonin synthesis was achieved with lower and less frequent dosing and at lower drug exposure levels than was observed with Lexicon's first generation serotonin synthesis inhibitor, LX1031, which had previously demonstrated clinical benefit to IBS patients in a Phase 2a clinical trial as measured by both global assessment of adequate relief and stool consistency.

"Based on the completed LX1033 Phase 1 program, we are confident that a convenient dose regimen of this compound can provide the level of serotonin reduction that we have previously associated with clinical benefit for patients with IBS-d," said Dr. Brian Zambrowicz, chief scientific officer at Lexicon.  "We were also impressed by the performance of the blood test for measuring 5-HIAA and anticipate using this biomarker to guide future drug development of LX1033."

The LX1033 Phase 1 trial was conducted as a
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/17/2013)... 17, 2013 Medical devices are any medical ... product. In light of their different mechanisms, actions and ... more complicated than drug trails due to their unique ... instead of evaluating both safety and efficacy (which is ... is the same as the SFDA) evaluate MDs for ...
(Date:5/17/2013)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... Global Healthcare Conference in New York . ... at 11 a.m. Eastern Time. To listen to the live ... Investor Relations section of the Company,s Web site at ... after the event. About Orexigen® Therapeutics Orexigen ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Statistical Challenges in Medical Device Trail Evaluation 2
... 15, 2011 Argon Medical Devices, Inc. announced ... with Rex Medical, LP ("Rex Medical") for exclusive global rights ... Filter, an implantable device used in the prevention of Pulmonary ... addition of Option™ to our product portfolio. This proven technology ...
... SAN DIEGO, March 15, 2011 OncoSec Medical, Inc. (OTC ... Punit Dhillon, President and CEO, will present a company overview ... ROTH 23rd Annual Growth Stock Conference being held at the ... Conference details: http://www.roth.com/main/Page.aspx?PageID=7236 ...
Cached Medicine Technology:Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... continue to mount in courts throughout the country, Bernstein ... that metal-on-metal hip replacement patients often suffer tissue damage ... During the study, which according to Science Daily will ... 69 metal-on-metal hip replacement recipients underwent MRI screens of ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices Market ... (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, ... the major market drivers, restraints, and opportunities in North ... Browse , 147 market data ... 318 pagesand in-depth TOC of “Sleep ...
(Date:5/18/2013)... The Ayurvedic practitioner program will be offered ... West. Program is available in Mexico via Live Internet ... modality practiced for over 5,000 years. In Ayurvedic medicine ... begins when an individual lives in harmony with their ... Ayurveda aims to heal an individual in all levels ...
(Date:5/18/2013)... Ca (PRWEB) May 18, 2013 Losing weight ... people. But among the horde of new weight loss products ... most talked about. Recent studies about this newest weight loss ... one’s ideal body shape. , Garcinia Cambogia is a sub-tropical ... a tamarind. Eating the fruit can suppress a person’s appetite, ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Miller has revealed that she has a great relationship with wine, ... . ,The 25-year-old said that she loves 'European and ... only increases each day. ,"We have been together for ... and more every day. I like European and all different types. ...
... pour in that US doctors tend to prescribe unwanted, even ... in the name of lecture assignments. ,Lawmakers ... makers to disclose payments made to doctors and also keep ... instance, earn more money from drug makers than doctors in ...
... UN report on drugs has officially declared Britain the cocaine ... Mail report, over 900,000 Britons buy cocaine, which means the ... continent. In addition, Britain's 350,000 heroin users are the largest ... annual survey from the UN's Office on Drugs and Crime ...
... Sheriff Lee Baca, who placed hotel heiress Paris Hilton ... that the socialite was suffering from a 'life-threatening' ... condition is the deterioration of one's mental state to ... ,Baca also said that the Simple Life star's ...
... is desperate to perform with, it would be British band Coldplay. ... the 'modern Beatles', and that's why he would give an arm ... in the band Timberlake knows just who he wants to jam ... the modern Beatles, so I'd love to do a duet with ...
... University has found that a patient's emotional state plays a ... ,After hip surgery, two tests are typically ... a clinical measure of hip function given by the doctor, ... a wide variety of factors in determining the overall success ...
Cached Medicine News:Health News:US Lawmakers Considering Legislation to Restrict Payments by Drug Companies to Doctors 2Health News:US Lawmakers Considering Legislation to Restrict Payments by Drug Companies to Doctors 3Health News:Emotions Play 'significant Role' in Recovery from Hip Surgery 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: